Natural Vitamin E Acetate (d-alpha tocopherol acetate, 1360IU/g)
Natural Vitamin E Acetate (d-alpha tocopheryl acetate, 1360IU/g) stabilized ester form of vitamin E widely used in dietary supplements, softgels and fortified foods where improved oxidative stability and processing robustness are required.
| Benefit | Typical study dose* | Key human findings | High-quality sources |
|---|---|---|---|
| 1 Vitamin E supplementation | ~100–400 IU/day (labelled as vitamin E, often as d-alpha tocopheryl acetate) with meals | Capsules and softgels using tocopheryl acetate maintain vitamin E status and provide antioxidant support comparable to free tocopherol at equal d-alpha IU; stability during storage is typically better. | PubMed |
| 2 Stability in finished products | Formulation-dependent; usually 10–400 IU per serving in supplements | Acetate ester resists oxidation during storage and during tableting, encapsulation and coating processes better than free tocopherol, supporting more predictable labelled potency over shelf life. | PubMed |
*IU values refer to labelled vitamin E activity as d-alpha tocopherol equivalents; regulations and formulations differ between markets.
Mechanistic highlights
- Ester pro-vitamin: Tocopheryl acetate is hydrolysed by esterases in the gut and tissues to release free d-alpha tocopherol, which then acts as the lipid-phase antioxidant.
- Improved oxidative robustness: The protected ester form is less reactive during manufacturing and storage, reducing peroxide formation and off-odors in high-fat matrices.
- Nutritional equivalence at equal IU: When converted to d-alpha tocopherol, tocopheryl acetate contributes to vitamin E status in a way that is practically similar to free tocopherol at the same labelled IU in healthy individuals.
Safety & practical use
- Usual supplemental range: 100–400 IU/day for adults, often provided as d-alpha tocopheryl acetate in capsules or softgels.
- Upper-dose considerations: As with other high-dose vitamin E preparations, long-term intakes at or above 400 IU/day should respect regional upper-intake limits and bleeding-risk considerations.
- Drug interactions: Monitor use with anticoagulant/antiplatelet medications and in people with bleeding disorders or vitamin K deficiency.
- Populations needing supervision: Pregnancy, breastfeeding, fat-malabsorption, severe liver disease, cancer therapy and other high-risk groups should be managed under medical guidance.
- Pale yellow to brownish-red viscous oily liquid
- Room (25-40C)
- 24 Months from manufacturing or testing date.
- 100mg - 400mg
- 200mg
- 100mg - 400mg
- 200mg
- Powder mixing for food/beverage (oil‑phase disperse or glycol premix)
- Heat Tolerant
- 0.00 - 0.00
- -
| Test Name | Specification |
|---|---|
| Characters | Pale yellow to brownish-red viscous oily liquid, practically insoluble in water, freely soluble in acetone, in anhydrous ethanol and in fatty oils. |
| Identification A | Color reaction is bright red or orange. |
| Identification B | Specific optical rotation ≥ +24°. |
| Identification C | The retention time of the major peak in the chromatogram of the Assay preparation is the same as that of the Standard preparation, both relative to the internal standard, as obtained in the Assay. |
| Acidity (0.10N NaOH) | ≤ 1.0 mL. |
| Heavy metals | ≤ 10 ppm. |
| Free tocopherol | ≤ 1.0%. |
| Assay | ≥ 96.0%. |
Cart
No products